Timed Up and Go test

Alterity Therapeutics Presents Promising Wearable Sensor Data from the bioMUSE Natural History Study at the American Academy of Neurology

Retrieved on: 
Wednesday, April 26, 2023
Multiple system atrophy, Gait, Vanderbilt University Medical Center, American Academy, ASX, Axovant Sciences, Biomarker, Timed Up and Go test, ATH, Walking, HIV disease progression rates, MD, Patient, MSA, SAN, Neurology, Poster, Principal, Biomusic, Disability studies, Therapy, Disease, Medical imaging

The poster, entitled, Wearable Sensors for Quantitative Motor Assessments in Multiple System Atrophy, was presented by Daniel Claassen, MD, Professor of Neurology at Vanderbilt University Medical Center, and Principal Investigator in the bioMUSE study.

Key Points: 
  • The poster, entitled, Wearable Sensors for Quantitative Motor Assessments in Multiple System Atrophy, was presented by Daniel Claassen, MD, Professor of Neurology at Vanderbilt University Medical Center, and Principal Investigator in the bioMUSE study.
  • The analysis was conducted to determine the utility of quantitative wearable sensors in 17 participants with early stage (less than three years of motor symptoms) multiple system atrophy (MSA).
  • “This analysis from bioMUSE demonstrates that wearable sensors can quantify motor impairment in MSA patients that is not captured by neurological examination,” said David Stamler, M.D., Chief Executive Officer, Alterity.
  • Specifically, sensor parameters correlated strongly with clinical scales of motor impairment and may be useful in assessing disease progression.

National Institute on Aging (NIA) awards $21M grant to support key phase 2b study of EIP Pharma's neflamapimod in dementia with Lewy bodies

Retrieved on: 
Wednesday, January 18, 2023
Disease, Attention, Brain, EEG, University, Caregiver, Lewy body, Even and odd functions, Biomarker, MD, Timed Up and Go test, DLB, Patient, NIA, Dementia, Alzheimer's disease, Neurodegeneration, NIH, Cognition, Pharmaceutical industry

The outcome of this phase 2b study could allow us to confirm the positive findings from our phase 2a study and definitively demonstrate the potential for neflamapimod to treat patients suffering from the second most common dementia, DLB.

Key Points: 
  • The outcome of this phase 2b study could allow us to confirm the positive findings from our phase 2a study and definitively demonstrate the potential for neflamapimod to treat patients suffering from the second most common dementia, DLB.
  • Therefore, it is with a heightened sense of responsibility and urgency that we look forward to moving the study forward with the phase 2b study commencing within the next few months".
  • Dr James Galvin from the University of Miami, co-principal investigator for the study, commented "DLB is the second most common neurodegenerative dementia, after Alzheimer's disease.
  • The NIA grant will fund a study that will be instrumental in fully understanding whether neflamapimod has the potential to become an important treatment for patients with DLB".

EIP Pharma Publishes Translational Data of Preclinical and Phase 2a Results for Neflamapimod in Dementia with Lewy Bodies: Nature Communications

Retrieved on: 
Wednesday, September 21, 2022
Professional Services, Health, Clinical Trials, Banking, Pharmaceutical, Biotechnology, Acetylcholine, Therapy, Neurodegeneration, Lists of diseases, Lewy body, Average absolute deviation, MAP, Ageing, FDA, MD, Food, Basal forebrain, Research, Brain, Government budget balance, Even and odd functions, Company, EIP, Nathan, Cognition, DLB, Patient, Neurological disorder, Attention, Timed Up and Go test, Center, TUG, Doctor of Philosophy, Nature Communications, Body, Drug development, CNS, NTB, Neuron, Lewy, Disease, Pharmaceutical industry, Dementia

The animal studies in the publication show that neflamapimod reduces Rab5 activity and reverses the neurodegenerative process in the basal forebrain.

Key Points: 
  • The animal studies in the publication show that neflamapimod reduces Rab5 activity and reverses the neurodegenerative process in the basal forebrain.
  • These combined pre-clinical and clinical results provide a foundation for a confirmatory, hypothesis-testing Phase 2b clinical study evaluating neflamapimod for DLB.
  • The data published today provide us confidence to progress neflamapimod into a confirmatory Phase 2b clinical trial in Dementia with Lewy Bodies.
  • et al., Preclinical and Randomized Clinical Evaluation of the p38 Kinase Inhibitor Neflamapimod for Basal Forebrain Cholinergic Degeneration, Nature Communications, 13, Article number: 5308 (2022).

New Clinical Study: Hinge Health Enso Wearable Demonstrates Significant Improvements in Both Mobility and Pain Reduction

Retrieved on: 
Wednesday, November 10, 2021
Hardware, Consumer Electronics, Insurance, Technology, Human Resources, Consulting, Surgery, Physical Therapy, General Health, Professional Services, Medical Devices, Fitness & Nutrition, Clinical Trials, Software, Alternative Medicine, Health, MSK, University, US Foods, New Jersey, Salesforce, San Francisco, Therapy, Organization, Trial of the century, Multimedia, Research, Digital, Verizon Communications, L.L.Bean, Southern Company, Pain, Timed Up and Go test, Preferred walking speed, Journal, Pain management, Randomized controlled trial, Physician, Patient, FDA, Medical imaging, Consumer electronics

A new randomized controlled clinical study finds that Hinge Healths Enso delivers 2x more pain reduction and improves mobility 3x compared to a control device.

Key Points: 
  • A new randomized controlled clinical study finds that Hinge Healths Enso delivers 2x more pain reduction and improves mobility 3x compared to a control device.
  • Enso, an FDA-cleared device, is a wearable, nonaddictive, high-frequency impulse therapy technology for better pain management and functional mobility.
  • View the full release here: https://www.businesswire.com/news/home/20211110005310/en/
    Randomized controlled clinical study demonstrates Hinge Healths Enso wearable delivers 2x more pain reduction and improves mobility 3x compared to a control device.
  • (Photo: Business Wire)
    Hinge Health Enso is one of the most advanced wearable technologies for electrical nerve stimulation.

EIP Pharma Announces New Data Presentations from Phase 2 Treatment Trial in Dementia with Lewy Bodies at Upcoming Scientific Conference and New Board Appointment

Retrieved on: 
Thursday, November 4, 2021
Neurology, Dementia, NTB, Alzheimer's disease, Harvard Medical School, Disease, Timed Up and Go test, Neurodegeneration, Neuron, TUG, CNS, Contribution, Patient, Policy, MAP, Communication, Lewy body, Center, Brain, Even and odd functions, MA, Cognition, NYU Langone Health, Board, Trial of the century, CEO, Attention, EIP, AD, DLB, News, McLean Hospital, Therapy, Barrow Neurological Institute, NYU, Board of directors, Clinical trial, Pharmaceutical industry, Generic drug

This poster will be both presented onsite during the meeting and will be available through CTAD's digital platform.

Key Points: 
  • This poster will be both presented onsite during the meeting and will be available through CTAD's digital platform.
  • In pre-clinical studies, neflamapimod reverses synaptic dysfunction, including and particularly within the part of the brain most impacted in dementia with Lewy bodies (DLB) - the basal forebrain cholinergic system.
  • Results from the AscenD-LB Phase 2 clinical study demonstrated proof of concept for neflamapimod as a treatment for DLB.
  • About EIP Pharma: EIP Pharma, Inc. is a private, Boston, MA company advancing CNS-focused therapeutics to benefit patients with neurodegenerative diseases.For more information, please visit www.eippharma.com

EIP Pharma appoints Dr. Marwan Sabbagh to Board of Directors

Retrieved on: 
Thursday, November 4, 2021
Dignity, Neurology, Research, NTB, Timed Up and Go test, Disease, Neurodegeneration, Neuron, TUG, Body, CNS, BioMed Central, Patient, MAP, Translational research, Lists of diseases, Lewy body, Brain, Hospital, Cleveland Clinic, Even and odd functions, MA, Cognition, Board, CEO, Attention, EIP, DLB, Memory, Therapy, Translation, Barrow Neurological Institute, Journal, Board of directors, Pharmaceutical industry

BOSTON, Nov. 4, 2021 /PRNewswire/ --EIP Pharma Inc., a clinical-stage pharma company focused on the development of disease-modifying treatments for dementia and neurodegenerative diseases announces the appointment of Dr. Marwan Sabbagh as non-executive director to its Board of Directors with immediate effect.

Key Points: 
  • BOSTON, Nov. 4, 2021 /PRNewswire/ --EIP Pharma Inc., a clinical-stage pharma company focused on the development of disease-modifying treatments for dementia and neurodegenerative diseases announces the appointment of Dr. Marwan Sabbagh as non-executive director to its Board of Directors with immediate effect.
  • Dr. Sabbagh is considered one of the leading experts in dementia and he has dedicated his career to finding a cure for age-related neurodegenerative diseases.
  • Sylvie Gregoire, executive-chair of the Board of EIP Pharma, said: "On behalf of the whole board I am very pleased to welcome Dr. Sabbagh to EIP Pharma.
  • About EIP Pharma: EIP Pharma, Inc. is a private, Boston, MA company advancing CNS-focused therapeutics to benefit patients with neurodegenerative diseases.